Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination chemotherapy regimen consisting of three drugs: - **5-fluorouracil** is an antimetabolite and pyrimidine analog that inhibits thymidylate synthase, disrupting DNA synthesis and function, leading to cell death. It is primarily used in the treatment of various solid tumors[5][7]. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA strands, preventing cell division and resulting in cytotoxicity. It has both cytotoxic and immunosuppressive properties[6][8]. - **Prednisolone** is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive effects; it also induces apoptosis in certain cancer cells. The combination of these agents leverages their complementary mechanisms for enhanced antitumor activity. While regimens containing similar combinations (often with additional agents like methotrexate or vincristine) have been studied for various cancers such as breast cancer, solid tumors, lymphoma, and multiple myeloma[1][2][6][8], the specific triplet of 5-fluorouracil + cyclophosphamide + prednisolone may be considered investigational or off-label as a defined protocol.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-fluorouracil + cyclophosphamide + prednisolone.